30.11.2021 • NewsNovozymesNovo Nordisk

Novozymes and Novo Nordisk Partner on Enzymes

Danish companies Novozymes and Novo Nordisk Pharmatech are teaming up to develop technical enzymes to support biopharma processing. The companies aim to develop high-quality enzymatic processing aids for the regenerative medicines market, focusing on stem cell and gene therapies.

“This collaboration reinforces a shared commitment to the development of specialty enzymes. Novo Nordisk Pharmatech brings market knowledge and the required production-quality capabilities, while Novozymes brings a large enzyme library and strong R&D competencies. Together, this positions us well to create new and innovative products for this market,” said Lotte Clemmen Christensen, vice president, corporate strategy & new business development at Novozymes

The partners expect to bring a first product to commercialization within a few years.

Author: Elaine Burridge, Freelance Journalist

Novozymes and Novo Nordisk Pharmatech are teaming up to develop best-in-class...
Novozymes and Novo Nordisk Pharmatech are teaming up to develop best-in-class technical enzymes to support biopharma processing. The companies aim to develop high-quality enzymatic processing aids for the regenerative medicines market, focusing on stem cell and gene therapies. (c) Novozymes

Free Virtual Event

Digital Validation
Transforming from Paper to Digital

Digital Validation

Our experts will delve into the recently released International Society for Pharmaceutical Engineering (ISPE) Good Practice Guide: Digital Validation

Interview

Specialty Chemicals in a Shifting World
Adapting to Tariffs and Strengthening Regional Networks

Specialty Chemicals in a Shifting World

Jennifer Abril, President & CEO of SOCMA, discusses the impact of new tariffs and the importance of regional supply networks in the specialty chemical industry.